- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
This Article
Services
Google Scholar
PubMed
Acta Endocrinologica (Buc)
Ji X, Shen L, Lin Z, Lv R
Comparative Growth Outcomes of Long-Acting and Short-Acting Growth Hormone Therapy in Pediatric Patients: A 12-Month Retrospective Analysis
Acta Endo (Buc) 2025, 21 (2): 219-226doi: 10.4183/aeb.2025.219
Background. Growth hormone (GH) therapy is
widely used for pediatric growth disorders, with short-acting
(Saizen) and long-acting (Jintropin) formulations available.
This study assesses height, weight, and bone age outcomes
in children treated with Jintropin, Saizen, or a combination
of both.
Methods. This retrospective cohort study (N=108)
compared Jintropin (n=31), Saizen (n=50), and Combination
Therapy (n=27). To control for baseline heterogeneity (age,
puberty) and repeated measures, analyses used ANCOVA
and LMM. Post-hoc comparisons used Bonferroni correction.
Safety was evaluated by ΔBA/ΔCA ratio.
Results. Following multivariable LMM adjustment,
the estimated marginal means for annualized GV were 9.30
cm/year (95% CI: 8.46–10.15) for Jintropin, 8.55 cm/year
(95% CI: 7.90–9.20) for Saizen, and 9.56 cm/year (95% CI:
8.77–10.34) for Combination Therapy. Adjusted pairwise
comparisons showed no significant efficacy differences
between groups (Jintropin vs. Saizen: p=0.501; Combination
vs. Saizen: p=0.160). Skeletal safety was confirmed across
cohorts (ΔBA/ΔCA: 0.34, 0.46, 0.68), indicating no
premature epiphyseal fusion.
Conclusion. Long-acting Jintropin monotherapy
provides growth outcomes comparable and non-inferior to
daily Saizen, offering a convenient, effective alternative that
reduces injection burden. The non-standard combination of
long- and short-acting GH showed no statistically superior
benefits, suggesting such complex regimens are unnecessary
in clinical practice.
Keywords: Growth hormone therapy, Jintropin, Saizen, height growth, BMI, bone age progression, recombinant human growth hormone (rhGH).
Correspondence: Xianli Ji MD, Department of Pediatrics, Yongkang First People's Hospital, No. 599, Jinshan West Road, Yongkang
City, Zhejiang Province, Postcode: 321300, Yongkang, China, E-mail: xianlijiaabb@yeah.net